Leber Hereditary Optic Neuropathy: Comprehensive Disease-Characteristics Report

Evidence scope. This report prioritizes peer-reviewed 2023–2024 literature, supplemented by landmark studies and current ClinicalTrials.gov records. Most information is aggregated disease-level evidence; the cited Madrid registry study used linked health records plus clinician-confirmed cases, while clinical trials and cohorts contain individual-participant observations. The report is not based on a single patient’s EHR.

Executive summary

Leber hereditary optic neuropathy (LHON) is an inherited mitochondrial neurodegenerative disorder characterized by selective loss of retinal ganglion cells (RGCs), producing rapid, painless, usually sequential bilateral central visual loss. Classical LHON is caused predominantly by one of three germline mitochondrial-DNA missense variants—m.11778G>A in MT-ND4, m.3460G>A in MT-ND1, and m.14484T>C in MT-ND6—which impair respiratory-chain complex I. Recently recognized, clinically similar autosomal-recessive forms result from biallelic nuclear variants, particularly in DNAJC30, and less commonly NDUFS2, NDUFA12, MCAT, and possibly other complex-I-associated genes. Incomplete, sex- and age-dependent penetrance means that carrying a pathogenic variant is not equivalent to developing optic neuropathy. (zeppieri2025isolatedandsyndromic pages 2-4, morgia2024recognizingleber’shereditary pages 1-2, lee2024hereditaryopticneuropathies pages 1-2, layrolle2024theopticnerve pages 2-4)

The upstream lesion is defective complex-I electron transfer; downstream consequences include impaired oxidative phosphorylation, reduced ATP reserve, excess reactive oxygen species, altered mitochondrial homeostasis, and apoptosis of metabolically vulnerable RGCs—especially small-caliber axons of the papillomacular bundle. This explains the characteristic central/centrocecal scotoma, dyschromatopsia, and eventual optic atrophy. (esmaeil2023leber’shereditaryoptic pages 1-2, layrolle2024theopticnerve pages 1-2, layrolle2024theopticnerve pages 2-4)

The principal disease-specific treatment is idebenone, authorized in Europe, commonly administered at 300 mg three times daily. Early and sufficiently prolonged therapy is favored. AAV2-mediated allotopic ND4 gene replacement has produced sustained bilateral improvements in trials, but contralateral improvement after unilateral injection complicates efficacy interpretation; it was not established routine clinical care in the 2023–2024 evidence base. (lee2024hereditaryopticneuropathies pages 2-4, lee2024hereditaryopticneuropathies pages 4-5, NCT02652767 chunk 1, NCT03406104 chunk 1, NCT03293524 chunk 1)

Table: This compact table organizes gathered Leber hereditary optic neuropathy facts into knowledge-base-ready domains, including identifiers, genetics, phenotypes, mechanisms, diagnostics, treatment, epidemiology, and models. Ontology and identifier fields are suggested conservatively, with uncertain IDs clearly marked for later verification.

1. Disease information

Definition and identifiers

LHON is a primary inherited optic neuropathy and mitochondrial disease causing acute/subacute degeneration of RGCs and the optic nerve.

• MONDO: MONDO:0010788.
• OMIM: #535000, LHON; autosomal-recessive LHON #619382.
• MeSH: D029242, Optic Atrophy, Hereditary, Leber.
• Autosomal-recessive MONDO entry: MONDO:0030309.
• Orphanet: commonly indexed as ORPHA:104; this identifier should be validated against the current Orphanet release before production ingestion.
• ICD: LHON is generally coded within hereditary optic atrophy/optic-nerve disorder categories rather than by a uniformly implemented disease-specific ICD-10 code. Country-specific mappings and the current ICD-11 browser should therefore be checked before deployment.

Open Targets associates MONDO:0010788 most strongly with MT-ND1, MT-ND4, MT-ND6 and other mitochondrial genes, and recognizes DNAJC30/NDUFS2 associations for autosomal-recessive LHON. (OpenTargets Search: Leber hereditary optic neuropathy, lee2024hereditaryopticneuropathies pages 1-2, layrolle2024theopticnerve pages 1-2, NCT01892943 chunk 1)

Synonyms: Leber hereditary optic neuropathy; Leber’s hereditary optic neuropathy; LHON; Leber hereditary optic atrophy; hereditary optic atrophy, Leber type. It must not be confused with Leber congenital amaurosis, a different retinal dystrophy.

2. Etiology, risk, and protective factors

Causal factors

Approximately 90–95% of molecularly resolved classical cases carry one of three mtDNA variants: m.11778G>A (MT-ND4; usually the most frequent), m.3460G>A (MT-ND1), or m.14484T>C (MT-ND6). These are germline, maternally transmitted missense variants, usually homoplasmic, affecting complex-I subunits. More than 50 rarer mtDNA variants have been reported, but pathogenicity requires careful evaluation because mtDNA variation is common. (morgia2024recognizingleber’shereditary pages 1-2, lee2024hereditaryopticneuropathies pages 1-2, layrolle2024theopticnerve pages 2-4)

Autosomal-recessive LHON phenocopies classical disease. DNAJC30 is particularly important in Eastern and Central European populations; biallelic NDUFS2, MCAT, NDUFA12, and reported NDUFAF5 defects should be considered when the phenotype is convincing but mtDNA testing is unrevealing. These discoveries overturn the older assumption that all LHON is maternally inherited. (zeppieri2025isolatedandsyndromic pages 2-4, lee2024hereditaryopticneuropathies pages 1-2)

Genetic susceptibility and modifiers

Penetrance is incomplete. Older estimates were approximately 40–50% in male and 10% in female carriers; more recent family data cited in 2024 guidance estimate 17.5% in males and 5.4% in females. Differences reflect ascertainment, genotype, age, ancestry, exposure, and family structure. Male predominance is not explained by mtDNA inheritance alone; estrogen-enhanced mitochondrial biogenesis and antioxidant defenses are a plausible protective mechanism, but not a clinically validated prophylaxis. (lee2024hereditaryopticneuropathies pages 2-4, morgia2024recognizingleber’shereditary pages 1-2, lee2024hereditaryopticneuropathies pages 1-2, layrolle2024theopticnerve pages 1-2)

Mitochondrial haplogroup, heteroplasmic load, nuclear background, and mitochondrial biogenesis influence expression, although no single modifier predicts conversion adequately. A clinically relevant 2024 development is evidence that variants lowering NQO1 protein can impair activation/effectiveness of idebenone, making NQO1 a candidate pharmacogenetic response modifier rather than a primary cause. (lee2024hereditaryopticneuropathies pages 4-5)

Environmental and lifestyle risks

Smoking is the best-supported modifiable risk factor. Heavy alcohol use is also associated with conversion, probably through oxidative stress, nutritional deficiency, and mitochondrial toxicity; the evidence for moderate alcohol is weaker. Other reported precipitating contexts include nutritional deficiency, severe illness, mitochondrial-toxic medicines, occupational toxins, and some antiretroviral, antitubercular, or toxic-optic-neuropathy drugs, but most drug associations rest on case reports rather than controlled estimates. There is no infectious cause and no zoonotic transmission. (esmaeil2023leber’shereditaryoptic pages 1-2, layrolle2024theopticnerve pages 1-2, lee2024hereditaryopticneuropathies pages 4-5)

A prospective cohort of 244 carriers/patients found vitamin-B12 deficiency in 21% of carriers younger than 65 versus 5–7% in the comparison population; excessive alcohol was a significant predictor. This does not prove that B12 deficiency triggers conversion, but supports periodic screening and correction.

Protective factors and gene–environment interaction

Recommended risk reduction consists of smoking abstinence, avoiding binge/heavy alcohol use, maintaining adequate nutrition—especially B12—and avoiding unnecessary mitochondrial/optic-nerve toxins. No medication has proven primary prophylactic efficacy in unaffected carriers. The conceptual interaction is: pathogenic complex-I genotype → reduced bioenergetic reserve → sex/nuclear/mtDNA-background modulation → environmental oxidative or nutritional stress → threshold crossing → RGC dysfunction and death. (layrolle2024theopticnerve pages 1-2, lee2024hereditaryopticneuropathies pages 4-5)

3. Phenotypes

Core ocular phenotype

The typical patient is an otherwise healthy adolescent or young adult, often male, with painless blurring and impaired color vision in one eye, followed by the fellow eye within approximately 6–12 weeks or 2–3 months. Simultaneous bilateral onset occurs in roughly 25–50% in older series. Visual acuity frequently deteriorates to worse than 20/200, counting fingers, or poorer, with a dense central or centrocecal scotoma and markedly impaired contrast and color discrimination. Relative afferent pupillary asymmetry may be absent once disease is bilateral. (zeppieri2025isolatedandsyndromic pages 2-4, esmaeil2023leber’shereditaryoptic pages 1-2, lee2024hereditaryopticneuropathies pages 2-4, morgia2024recognizingleber’shereditary pages 1-2)

Acute fundus signs include optic-disc hyperemia, circumpapillary telangiectatic microangiopathy, vascular tortuosity, and pseudoedema/RNFL swelling without typical fluorescein leakage. Macular ganglion-cell thinning can precede symptoms, while peripapillary RNFL initially thickens and then becomes severely thin. Chronic disease produces temporal and subsequently diffuse optic pallor. (zeppieri2025isolatedandsyndromic pages 2-4, esmaeil2023leber’shereditaryoptic pages 1-2, morgia2024recognizingleber’shereditary pages 1-2, layrolle2024theopticnerve pages 2-4)

Suggested HPO annotations: optic atrophy (HP:0000648); reduced visual acuity; central/centrocecal scotoma; color-vision defect/dyschromatopsia; painless visual loss; retinal nerve-fiber-layer thinning; optic-disc pallor; vascular tortuosity. Exact HPO identifiers other than HP:0000648 should be validated against the current HPO release.

Frequency, onset, severity, and progression

Peak onset is approximately 15–30 years; reported onset spans about 2–90 years, and around 10% may present after 50. Mean onset is approximately 25 years in males and 30 in females. Vision often reaches a nadir or plateau near four months. Most macular RGC loss is completed in the first six months, although anatomic degeneration may continue after functional stabilization. Childhood onset, especially before age 9–12, is less typical and often has a better prognosis. (zeppieri2025isolatedandsyndromic pages 2-4, esmaeil2023leber’shereditaryoptic pages 1-2, lee2024hereditaryopticneuropathies pages 2-4)

LHON-plus

A minority develop extraocular disease—movement disorders, dystonia, tremor, parkinsonism, ataxia, epilepsy, myoclonus, peripheral neuropathy, myopathy, encephalopathy, cardiac conduction abnormalities, or endocrine dysfunction. Coexisting LHON and multiple-sclerosis-like disease is termed Harding disease and is reported disproportionately in women. In one cited imaging cohort, as many as 25% of 31 patients had MS-like T2 lesions, but causal overlap remains uncertain. (lee2024hereditaryopticneuropathies pages 2-4, layrolle2024theopticnerve pages 2-4)

Quality of life

Severe central visual loss impairs reading, driving, education, employment, facial recognition, and independent navigation, with substantial psychological effects. A 2024 Slovenian study of nine adults—one-third of known national cases—reported mean VFQ-25 of 30.4/100 (SD 12.9) and estimated annual productivity loss of €11,608 per affected person. Its small sample limits generalizability, but quantifies the major real-world burden.

4. Genetic and molecular information

Variant classes and population frequency

The three primary variants are germline mtDNA single-nucleotide missense substitutions. They are commonly homoplasmic, so a conventional nuclear-variant allele frequency is not directly applicable. Population genomic studies find primary LHON susceptibility variants in approximately 1/800–1/1,000 people—far more common than manifest disease—illustrating low penetrance and the danger of interpreting genotype without phenotype and pedigree. Heteroplasmic cases require quantification in blood and, if suspicion remains, another tissue because heteroplasmy may vary by tissue. (layrolle2024theopticnerve pages 1-2, layrolle2024theopticnerve pages 2-4)

Nuclear arLHON variants are biallelic germline variants and can include missense, frameshift, nonsense, and splice-altering alleles. Classification should follow ACMG/AMP criteria with segregation, population frequency, phenotype, and functional evidence; ClinVar assertions must be reviewed variant by variant. Somatic mutation is not the usual etiology. Large chromosomal abnormalities, repeat expansions, aneuploidy, and translocations are not established causes, so karyotype, FISH, and chromosomal microarray are low-yield in a typical isolated LHON phenotype.

Epigenetics and omics

No validated disease-defining methylation, histone, or chromatin signature is used clinically. Transcriptomic work in patient-specific RGCs has implicated altered glutamatergic/AMPA-receptor signaling; cellular models also demonstrate abnormal mitochondrial transport, bioenergetics, apoptosis susceptibility, and mitophagy. These remain research findings rather than diagnostic biomarkers. Single-cell and spatial-transcriptomic human data are still limited, largely because affected retinal and optic-nerve tissue is inaccessible.

5. Environmental information

Tobacco smoke and heavy alcohol are the principal actionable exposures. Nutritional insufficiency, particularly B12 deficiency, may compound mitochondrial dysfunction. Occupational solvent/toxin exposure should be elicited because toxic optic neuropathy both mimics and may aggravate LHON. Radiation, pollution, and exercise have no established disease-specific causal estimates. There is no recognized bacterial, viral, fungal, or parasitic etiology. (esmaeil2023leber’shereditaryoptic pages 1-2, layrolle2024theopticnerve pages 1-2)

6. Mechanism and pathophysiology

Causal chain

1. Upstream genetic lesion: defective mtDNA- or nuclear-encoded complex-I component/maintenance protein.
2. Respiratory dysfunction: impaired NADH-to-ubiquinone electron transfer and reduced proton-gradient efficiency.
3. Metabolic stress: diminished ATP reserve, altered NADH/NAD+ redox balance, and increased electron leak/ROS.
4. Cellular response: altered mitochondrial dynamics, transport, mitophagy, membrane potential, calcium/redox signaling, and heightened apoptotic susceptibility.
5. Selective tissue injury: RGC somata and their long, partly unmyelinated, energy-intensive axons—especially the papillomacular bundle—fail.
6. Clinical manifestation: central/centrocecal field loss, dyschromatopsia, severe central acuity loss, RNFL/GCL thinning, and optic atrophy. (layrolle2024theopticnerve pages 1-2, layrolle2024theopticnerve pages 2-4)

Complex I is embedded in the mitochondrial inner membrane and normally oxidizes NADH while reducing ubiquinone. Idebenone’s rationale is to accept electrons through NQO1 and deliver them downstream to complex III, partly bypassing complex I while also limiting oxidative injury. (zeppieri2025isolatedandsyndromic pages 13-14, lee2024hereditaryopticneuropathies pages 4-5, layrolle2024theopticnerve pages 2-4)

Suggested GO terms: oxidative phosphorylation (GO:0006119); apoptotic process (GO:0006915); mitochondrial electron transport, NADH to ubiquinone; ATP synthesis coupled electron transport; reactive-oxygen-species metabolic process; mitophagy; mitochondrial transport. GO cellular components: mitochondrion (GO:0005739), mitochondrial inner membrane (GO:0005743), respiratory-chain complex I. Cell Ontology: retinal ganglion cell; astrocyte and oligodendrocyte may be secondary participants. Exact current IDs should be release-validated.

Immune activation is not the primary mechanism, although secondary gliosis/inflammation may accompany degeneration. MRI abnormalities can resemble inflammatory demyelination, explaining frequent misdiagnosis.

7. Anatomical structures affected

The primary organ is the eye/afferent visual system. At tissue level, the retinal ganglion-cell layer, RNFL, optic disc, papillomacular bundle, and optic nerve are affected. MRI and pathology show downstream involvement of optic chiasm, optic tracts, lateral geniculate nuclei, optic radiations, and visual cortex. Histopathology has found up to approximately 95% reduction in temporal fibers and 40% reduction in optic-nerve cross-sectional area compared with controls. Disease is ultimately bilateral, often sequential and mildly asymmetric early. (layrolle2024theopticnerve pages 2-4)

Suggested UBERON: retina (UBERON:0000966), optic nerve, optic chiasm, optic tract, lateral geniculate nucleus, and visual cortex; validate exact release-specific IDs. Subcellular localization is the mitochondrial inner membrane/complex I.

8. Temporal development

A practical staging system is:

• Asymptomatic carrier: normal acuity, although subtle color, electrophysiologic, OCT, or microvascular abnormalities may occur.
• Subacute, <6 months: rapid visual decline, disc hyperemia/telangiectasia, RNFL swelling, early GCL loss.
• Dynamic, 6–12 months: continued structural loss, transition from swelling to atrophy; some eyes begin recovery.
• Chronic, >12 months: stable severe central deficit and optic atrophy, with possible delayed recovery.

The fellow eye is most vulnerable in the first weeks to months. This and the period before extensive GCL/RNFL loss constitute the strongest opportunity for intervention. Spontaneous or treatment-associated improvement may begin after approximately one year and continue for years; it is recovery rather than true remission because the causal genotype persists. (zeppieri2025isolatedandsyndromic pages 2-4, lee2024hereditaryopticneuropathies pages 2-4, iorga2025evaluationofvisual pages 1-2, catarino2017useofidebenone pages 5-6)

9. Inheritance and population

Classical LHON is maternally inherited: all children of a woman carrying the mtDNA variant may inherit it, while affected men do not transmit their mtDNA. Penetrance is incomplete, age-dependent, sex-biased, and family-specific. Expressivity is variable; anticipation is not established. Germline mosaicism is less relevant than heteroplasmy/mitotic segregation. Consanguinity is not important for classical mtLHON but may increase arLHON risk. Nuclear arLHON follows autosomal-recessive inheritance, giving a 25% affected-child risk when both parents carry pathogenic alleles in the same gene.

Manifest-disease prevalence in Europe is often reported between 1/27,000 and 1/50,000. A rigorous 2024 Madrid study identified 37 confirmed cases: observed prevalence 0.55/100,000 and capture–recapture prevalence 0.79/100,000, 43.6% higher than observed; sex-specific estimates were 1.15/100,000 in men and 0.43/100,000 in women, with a male:female ratio of 2.4:1. This study also showed that automated health-record ascertainment had low positive predictive value, emphasizing clinician confirmation. (zeppieri2025isolatedandsyndromic pages 2-4, esmaeil2023leber’shereditaryoptic pages 1-2, morgia2024recognizingleber’shereditary pages 1-2)

Founder effects occur: m.14484T>C is enriched in some French-Canadian pedigrees, while DNAJC30 p.Tyr51Cys is prominent in Eastern Europe. Carrier frequency is much higher than disease prevalence because penetrance is low.

10. Diagnostics

Clinical and functional evaluation

Urgent neuro-ophthalmic assessment should document best-corrected visual acuity, color vision, contrast sensitivity, automated visual fields, pupils, dilated fundus examination, fundus photography, and spectral-domain OCT of peripapillary RNFL and macular GCL/GCC. OCT can reveal GCL loss before obvious optic atrophy and helps distinguish LHON from inflammatory optic neuritis. Visual evoked potentials and pattern electroretinography/photopic negative response can document RGC dysfunction but are not required for molecular confirmation. MRI of brain and orbits with contrast is useful in atypical cases to exclude inflammation, compression, and demyelination; LHON can nevertheless show optic-nerve/chiasmal T2 abnormalities. (esmaeil2023leber’shereditaryoptic pages 1-2, morgia2024recognizingleber’shereditary pages 1-2, layrolle2024theopticnerve pages 2-4, NCT02652767 chunk 2)

Routine blood tests should be directed at mimics or modifiers: B12 with methylmalonic acid/homocysteine when indicated, folate, thiamine, copper, CBC, metabolic panel, and toxic-exposure testing. Lactate may be normal and is neither sensitive nor specific. Biopsy is generally unnecessary.

Genetic workflow

1. Test blood for m.11778G>A, m.3460G>A, and m.14484T>C.
2. If negative but suspicion remains, sequence the entire mitochondrial genome with heteroplasmy-sensitive methods and assess deletion/coverage quality.
3. If mtDNA testing is unrevealing, use an inherited-optic-neuropathy/nuclear mitochondrial panel including at least DNAJC30, NDUFS2, NDUFA12, MCAT, NDUFAF5, and differential genes such as OPA1.
4. WES/WGS is useful for unresolved or syndromic disease; WGS may better capture mtDNA and structural/noncoding variation, but laboratory validation is required.
5. Test the maternal lineage or siblings for segregation and counseling. (morgia2024recognizingleber’shereditary pages 1-2, lee2024hereditaryopticneuropathies pages 1-2)

CMA, karyotyping, FISH, and repeat-expansion tests are not first-line. RNA-seq, proteomics, metabolomics, epigenomics, and liquid biopsy are investigational, not standard diagnostics.

Differential diagnosis

Major alternatives are inflammatory optic neuritis associated with multiple sclerosis, AQP4-NMOSD or MOGAD; dominant optic atrophy; toxic/nutritional optic neuropathy; compressive optic neuropathy; ischemic optic neuropathy; glaucoma; macular disease; and other mitochondrial syndromes. LHON is favored by painless sequential central loss, male/maternal pedigree, disc telangiectasia without leakage, early macular GCL loss, poor spontaneous early recovery, and a pathogenic genotype. Prompt distinction matters because corticosteroids/plasma exchange treat inflammatory disease but not primary LHON. (morgia2024recognizingleber’shereditary pages 1-2)

No population newborn screening is established. Cascade testing of maternal relatives and targeted testing of at-risk siblings in arLHON are appropriate after counseling.

11. Outcome and prognosis

LHON usually does not directly shorten life expectancy, and disease-specific survival statistics are not meaningful for isolated disease. Morbidity is substantial because severe central blindness occurs during education and working life. LHON-plus disease may add neurologic or cardiac risk and warrants phenotype-directed surveillance.

Spontaneous recovery is genotype-dependent: approximately 37–71% or as high as 70% for m.14484T>C, 4–23% for m.11778G>A, and 15–25% for m.3460G>A in cited series. Recovery definitions and follow-up differ substantially. Favorable factors include m.14484T>C, younger/childhood onset, larger residual RNFL/GCL reserve, and possibly earlier treatment; m.11778G>A generally has the poorest natural prognosis. (morgia2024recognizingleber’shereditary pages 1-2, catarino2017useofidebenone pages 5-6)

12. Treatment

Idebenone

Idebenone is a short-chain benzoquinone/CoQ analog and antioxidant. The standard European regimen is 900 mg/day—300 mg three times daily with food. Consensus practice favors initiation as soon as possible, preferably within one year of onset, and continuation for at least one year; because recovery can be delayed, two years or continuation until a stable plateau is often considered. It is the only EMA-authorized disease-specific treatment in the gathered evidence. (lee2024hereditaryopticneuropathies pages 2-4, catarino2017useofidebenone pages 5-6, zeppieri2025isolatedandsyndromic pages 13-14)

RHODOS enrolled 85 patients and missed its prespecified primary endpoint, but secondary analyses favored idebenone. LEROS compared 199 treated patients with 372 external natural-history controls and found significantly more clinically relevant benefit at 12 months. Benefit varied by stage and genotype: subacute/dynamic benefit was clearest for m.11778G>A; chronic m.11778G>A and m.14484T>C groups showed consistent benefit, whereas m.3460G>A showed less effect. This is meaningful but not equivalent to a contemporaneous randomized comparison. (lee2024hereditaryopticneuropathies pages 2-4, lee2024hereditaryopticneuropathies pages 4-5)

Common trial adverse events were generally mild—nasopharyngitis 25.5%, headache 23.6%, and cough 10.9% in the cited RHODOS analysis. Candidate NQO1 low-expression genotypes may predict poorer response, but routine NQO1-guided prescribing is not yet established. (catarino2017useofidebenone pages 5-6, lee2024hereditaryopticneuropathies pages 4-5)

NCIt suggestions: Idebenone; antioxidant; pharmacologic intervention. Verify current NCIt concept codes before ingestion.

Gene therapy

Lenadogene nolparvovec (GS010) uses intravitreal rAAV2/2 to deliver a nuclear-compatible wild-type ND4 with a mitochondrial targeting sequence—allotopic expression. RESCUE was a randomized, quadruple-masked phase III trial in 39 patients with ≤6 months’ visual loss; one eye received 9×10^10 vector genomes and the fellow eye sham. Both eyes improved, undermining the within-patient comparison, plausibly because vector/DNA or biological signaling crossed the optic pathways. (lee2024hereditaryopticneuropathies pages 4-5, NCT02652767 chunk 1)

REFLECT enrolled 98 patients with ≤1 year of loss and compared bilateral active injection with active first-eye/placebo fellow-eye treatment. RESTORE followed 62 RESCUE/REVERSE participants to five years and assessed BCVA, clinically relevant recovery, adverse events, and VFQ-25 quality of life. These studies support durable biological activity, but bilateral improvement after unilateral dosing, natural recovery, and absence of an independent untreated group limit causal effect estimates. (NCT03406104 chunk 1, NCT03293524 chunk 1)

Relevant records and URLs:

• RESCUE, NCT02652767: https://clinicaltrials.gov/study/NCT02652767.
• RESTORE, NCT03406104: https://clinicaltrials.gov/study/NCT03406104.
• REFLECT, NCT03293524: https://clinicaltrials.gov/study/NCT03293524.
• Historical natural history, NCT01892943, 306 records: https://clinicaltrials.gov/study/NCT01892943. (NCT01892943 chunk 1, NCT02652767 chunk 1, NCT03406104 chunk 1, NCT03293524 chunk 1)

As of the 2023–2024 literature, gene therapy remained investigational/not routine, and the European marketing application had been withdrawn. New trials should not be represented as approved care. NCIt suggestions: gene therapy (NCIt C15238), viral-vector therapy, intravitreal injection.

Other and supportive approaches

Brimonidine, cyclosporine, EPI-743/vatiquinone, elamipretide, bezafibrate, nicotinamide, mitochondrial biogenesis agents, stem cells, and mitochondrial gene editing/replacement remain experimental or unsupported for routine LHON care. The completed bezafibrate trial is NCT04561466; early rAAV2-ND4 studies include NCT01267422 and NCT03153293. No surgery restores the optic nerve. Low-vision rehabilitation, assistive technology, orientation/mobility training, occupational/educational accommodations, psychological care, and management of depression are essential. (zeppieri2025isolatedandsyndromic pages 13-14, lee2024hereditaryopticneuropathies pages 4-5)

13. Prevention

Primary prevention in carriers: do not smoke; avoid heavy alcohol and recreational/occupational mitochondrial toxins; maintain adequate nutrition; screen and treat B12 deficiency; review potentially optic-toxic drugs; and educate carriers about urgent assessment for new color or central-vision changes. No vaccine or proven prophylactic medicine applies.

Secondary prevention: cascade genetic testing, baseline neuro-ophthalmic assessment, rapid OCT/genetic confirmation after first-eye symptoms, and early idebenone where locally indicated. Routine population screening is not justified by current evidence.

Tertiary prevention: protect residual vision, avoid further mitochondrial insults, treat systemic LHON-plus disease, provide low-vision and psychological rehabilitation, and monitor the fellow eye during the high-risk interval.

Genetic counseling must explain maternal transmission, incomplete penetrance, inability to predict precisely who will convert, and different autosomal-recessive risks. Reproductive options include prenatal testing and preimplantation genetic testing; mitochondrial donation/replacement is jurisdiction-dependent and raises regulatory and ethical issues.

14. Other species and natural disease

No well-established, naturally occurring companion-animal or livestock disease is accepted as a direct LHON ortholog, and LHON has no zoonotic potential. Complex-I genes and RGC bioenergetics are deeply conserved, but veterinary optic neuropathies should not automatically be labeled LHON. Accordingly, no reliable VBO breed association or nonhuman natural-disease prevalence can be assigned from current evidence.

Nonhuman primates have been used to study AAV2 vector trafficking: vector transfer toward the contralateral optic pathway offers a mechanistic explanation for bilateral improvement after unilateral treatment. This is an induced experimental observation, not natural disease. (lee2024hereditaryopticneuropathies pages 4-5)

15. Model organisms and experimental systems

Cybrids and fibroblasts: Patient mtDNA can be placed in a standardized nuclear background to isolate mitochondrial effects. Cybrids reproduce complex-I/ROS phenotypes but are often non-neuronal and cannot model tissue architecture or sex/environmental penetrance.

Patient-derived iPSC-RGCs: These preserve patient nuclear and mitochondrial backgrounds. LHON-RGCs show abnormal morphology, reduced mitochondrial function/transport, altered signaling, and increased death. In a mitochondrial-replacement model, replacing mutant mtDNA generated isogenic corrected cells and rescued the increased RGC-death phenotype. These models support causality and are useful for drug screening, but differentiation variability and immature cellular state remain limitations.

Retinal organoids: Three-dimensional systems improve cell–cell context and can model RGC/axon loss, mitochondrial membrane-potential and ATP defects, and mitophagy. They still lack a mature vascularized optic nerve and long-range brain connections.

Rodent models: Induced complex-I-deficient and allotopic ND4-expression models reproduce selected RGC loss or treatment biology. No mouse fully captures human incomplete penetrance, maternal pedigree, papillomacular-bundle anatomy, and sequential bilateral onset. Ndufs4 models are broader complex-I disease models rather than exact classical LHON.

Applications: mechanism dissection, modifier validation, AAV biodistribution/safety, idebenone and antioxidant testing, CRISPR/mitochondrial-editing feasibility, and biomarker development. Robust translational conclusions require convergence across human cohorts, isogenic cells, organoids, and in-vivo systems.

Recent developments and expert assessment

1. Recognition of nuclear arLHON (2023): DNAJC30 and additional nuclear genes require a diagnostic pathway beyond the three primary mtDNA variants, particularly in Eastern European cases. This is a major shift from the historical “exclusively maternal” model. (zeppieri2025isolatedandsyndromic pages 2-4, lee2024hereditaryopticneuropathies pages 1-2)
2. Improved diagnostic guidance (2024): experts emphasize early OCT recognition and immediate targeted mtDNA testing to avoid misdiagnosis as optic neuritis, followed by full mtDNA sequencing and nuclear testing when necessary. (morgia2024recognizingleber’shereditary pages 1-2)
3. Population ascertainment (2024): the Madrid capture–recapture study showed that routine administrative sources undercount LHON and have poor positive predictive value without clinician validation. This argues for specialist-confirmed rare-disease registries.
4. Pharmacogenetic refinement (2024): NQO1 expression variants may explain some idebenone nonresponse, but prospective validation is required before genotype-guided therapy. (lee2024hereditaryopticneuropathies pages 4-5)
5. Gene-therapy interpretation: long-term improvement is encouraging, but contralateral-eye improvement after unilateral injection means that the fellow eye is not a true independent placebo. Authoritative reviews therefore regard allotopic therapy as promising but not yet definitive routine treatment. (lee2024hereditaryopticneuropathies pages 4-5, NCT02652767 chunk 1, NCT03406104 chunk 1)

Key source links and publication dates

• Esmaeil A, Ali A, Behbehani R. Frontiers in Ophthalmology, January 2023. DOI: https://doi.org/10.3389/fopht.2022.1077395. The abstract summarizes LHON as respiratory-chain dysfunction that “eventually leads to apoptosis of retinal ganglion cells.” (esmaeil2023leber’shereditaryoptic pages 1-2)
• Lenaers G et al. Brain, April 2023. DOI: https://doi.org/10.1093/brain/awad131. Abstract: “The discovery of arLHON cases breaks with the dogma of exclusive maternal inheritance.” (zeppieri2025isolatedandsyndromic pages 2-4)
• Layrolle P et al. Biomedicines, March 2024. DOI: https://doi.org/10.3390/biomedicines12030584. Abstract: “Environmental factors are critical in LHON triggering or severity.” (layrolle2024theopticnerve pages 1-2)
• Lee SK et al. Journal of Clinical & Translational Ophthalmology, June 2024. DOI: https://doi.org/10.3390/jcto2030006. (lee2024hereditaryopticneuropathies pages 2-4, lee2024hereditaryopticneuropathies pages 4-5)
• La Morgia C et al. Frontiers in Neurology, September 2024. DOI: https://doi.org/10.3389/fneur.2024.1466275. Abstract: “Given the availability of a specific treatment for LHON, its early diagnosis is imperative.” (morgia2024recognizingleber’shereditary pages 1-2)
• Open Targets disease–target evidence, accessed through MONDO:0010788. (OpenTargets Search: Leber hereditary optic neuropathy)

Evidence gaps and curation cautions

Incidence is poorly quantified; prevalence varies with ascertainment and founder effects. Exact phenotype frequencies outside the core ocular syndrome are uncertain. No validated epigenetic or circulating biomarker predicts conversion. Environmental associations beyond smoking/heavy alcohol are mostly observational. Idebenone evidence combines randomized, follow-up, real-world, and externally controlled data with different recovery definitions. Gene-therapy efficacy remains difficult to isolate from natural recovery and bilateral vector effects. Ontology identifiers marked “verify” in the embedded table should be checked against current HPO, GO, CL, UBERON, CHEBI, NCIt, ICD-11, and Orphanet releases before database ingestion.

References

1. (zeppieri2025isolatedandsyndromic pages 2-4): Marco Zeppieri, Caterina Gagliano, Marco Di Maita, Alessandro Avitabile, Giuseppe Gagliano, Edoardo Dammino, Daniele Tognetto, Maria Francesca Cordeiro, and Fabiana D’Esposito. Isolated and syndromic genetic optic neuropathies: a review of genetic and phenotypic heterogeneity. International Journal of Molecular Sciences, 26:3892, Apr 2025. URL: https://doi.org/10.3390/ijms26083892, doi:10.3390/ijms26083892. This article has 5 citations.

2. (morgia2024recognizingleber’shereditary pages 1-2): Chiara La Morgia, Maria Lucia Cascavilla, Anna Maria De Negri, Marcello Romano, Fabrizio Canalini, Silvia Rossi, Diego Centonze, and Massimo Filippi. Recognizing leber’s hereditary optic neuropathy to avoid delayed diagnosis and misdiagnosis. Frontiers in Neurology, Sep 2024. URL: https://doi.org/10.3389/fneur.2024.1466275, doi:10.3389/fneur.2024.1466275. This article has 14 citations and is from a peer-reviewed journal.

3. (lee2024hereditaryopticneuropathies pages 1-2): Samuel K. Lee, Caroline Mura, Nicolas J. Abreu, Janet C. Rucker, Steven L. Galetta, Laura J. Balcer, and Scott N. Grossman. Hereditary optic neuropathies: an updated review. Journal of Clinical & Translational Ophthalmology, 2:64-78, Jun 2024. URL: https://doi.org/10.3390/jcto2030006, doi:10.3390/jcto2030006. This article has 5 citations.

4. (layrolle2024theopticnerve pages 2-4): Pierre Layrolle, Christophe Orssaud, Maryse Leleu, Pierre Payoux, and Stéphane Chavanas. The optic nerve at stake: update on environmental factors modulating expression of leber’s hereditary optic neuropathy. Biomedicines, 12:584, Mar 2024. URL: https://doi.org/10.3390/biomedicines12030584, doi:10.3390/biomedicines12030584. This article has 10 citations.

5. (esmaeil2023leber’shereditaryoptic pages 1-2): Ali Esmaeil, Ali Ali, and Raed Behbehani. Leber’s hereditary optic neuropathy: update on current diagnosis and treatment. Frontiers in Ophthalmology, Jan 2023. URL: https://doi.org/10.3389/fopht.2022.1077395, doi:10.3389/fopht.2022.1077395. This article has 34 citations.

6. (layrolle2024theopticnerve pages 1-2): Pierre Layrolle, Christophe Orssaud, Maryse Leleu, Pierre Payoux, and Stéphane Chavanas. The optic nerve at stake: update on environmental factors modulating expression of leber’s hereditary optic neuropathy. Biomedicines, 12:584, Mar 2024. URL: https://doi.org/10.3390/biomedicines12030584, doi:10.3390/biomedicines12030584. This article has 10 citations.

7. (lee2024hereditaryopticneuropathies pages 2-4): Samuel K. Lee, Caroline Mura, Nicolas J. Abreu, Janet C. Rucker, Steven L. Galetta, Laura J. Balcer, and Scott N. Grossman. Hereditary optic neuropathies: an updated review. Journal of Clinical & Translational Ophthalmology, 2:64-78, Jun 2024. URL: https://doi.org/10.3390/jcto2030006, doi:10.3390/jcto2030006. This article has 5 citations.

8. (lee2024hereditaryopticneuropathies pages 4-5): Samuel K. Lee, Caroline Mura, Nicolas J. Abreu, Janet C. Rucker, Steven L. Galetta, Laura J. Balcer, and Scott N. Grossman. Hereditary optic neuropathies: an updated review. Journal of Clinical & Translational Ophthalmology, 2:64-78, Jun 2024. URL: https://doi.org/10.3390/jcto2030006, doi:10.3390/jcto2030006. This article has 5 citations.

9. (NCT02652767 chunk 1): Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation. GenSight Biologics. 2016. ClinicalTrials.gov Identifier: NCT02652767

10. (NCT03406104 chunk 1): RESCUE and REVERSE Long-term Follow-up. GenSight Biologics. 2018. ClinicalTrials.gov Identifier: NCT03406104

11. (NCT03293524 chunk 1): Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year. GenSight Biologics. 2018. ClinicalTrials.gov Identifier: NCT03293524

12. (OpenTargets Search: Leber hereditary optic neuropathy): Open Targets Query (Leber hereditary optic neuropathy, 24 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

13. (NCT01892943 chunk 1): Leber Hereditary Optic Neuropathy (LHON) Historical Case Record Survey. Santhera Pharmaceuticals. 2013. ClinicalTrials.gov Identifier: NCT01892943

14. (iorga2025evaluationofvisual pages 1-2): Raluca Eugenia Iorga, Andreea Dana Moraru, Răzvana Sorina Munteanu-Dănulescu, Delia Urdea, and Ciprian Danielescu. Evaluation of visual and optical coherence tomography outcomes in patients with leber’s hereditary optic neuropathy treated with idebenone. Life, 15:1172, Jul 2025. URL: https://doi.org/10.3390/life15081172, doi:10.3390/life15081172. This article has 1 citations.

15. (NCT02652767 chunk 2): Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation. GenSight Biologics. 2016. ClinicalTrials.gov Identifier: NCT02652767

16. (catarino2017useofidebenone pages 5-6): Claudia B. Catarino and Thomas Klopstock. Use of idebenone for the treatment of leber’s hereditary optic neuropathy: review of the evidence. ArXiv, 5:232640981773111, Sep 2017. URL: https://doi.org/10.1177/2326409817731112, doi:10.1177/2326409817731112. This article has 10 citations.

17. (zeppieri2025isolatedandsyndromic pages 13-14): Marco Zeppieri, Caterina Gagliano, Marco Di Maita, Alessandro Avitabile, Giuseppe Gagliano, Edoardo Dammino, Daniele Tognetto, Maria Francesca Cordeiro, and Fabiana D’Esposito. Isolated and syndromic genetic optic neuropathies: a review of genetic and phenotypic heterogeneity. International Journal of Molecular Sciences, 26:3892, Apr 2025. URL: https://doi.org/10.3390/ijms26083892, doi:10.3390/ijms26083892. This article has 5 citations.

Artifacts

• Edison artifact artifact-00